Penn Cardiovascular Institute

History of the Penn Cardiovascular Institute

The Penn Cardiovascular Institute (CVI) in Philadelphia was established in 2005 to promote cardiovascular research and discovery across schools, institutes, centers, departments and divisions at the University of Pennsylvania. Put under the direction of Michael Parmacek, MD, a nationally recognized leader in cardiovascular research and chief of the Division of Cardiovascular Medicine, the Penn Cardiovascular Institute set out to unite and support the research of scientists and clinicians across Penn Medicine and the entire University of Pennsylvania campus.

Integrating Cardiovascular Research and Patient Care at Penn

The Penn Heart and Vascular Center is recognized as one of America’s best cardiology and heart surgery centers. The Penn Heart and Vascular Center and Penn CVI are integrated to provide personalized cardiovascular care using the latest medical research. In other words, heart and vascular research at Penn CVI is often developed into life-saving therapies for patients.

Growing Support for Heart Research in Philadelphia

Over the past decade, cardiovascular research and clinical care at the University of Pennsylvania and Penn Medicine has grown tremendously with many nationally and internationally recognized research and clinical programs. For the last three years, The National Institutes of Health has annually awarded Penn Medicine over $70 million in funding for cardiovascular research.

Today and Into the Future

  • Penn Medicine is one of the few institutions in the nation with a dedicated cardiovascular research laboratory.
  • Penn CVI faculty members are internationally distinguished for research in molecular cardiology, cardiovascular development and genetics, atherosclerosis, lipid biology, cardiac electrophysiology valvular heart disease and heart failure.
  • Penn CVI faculty members annually publish hundreds of manuscripts in the world’s leading journals.
  • Penn has been awarded several highly competitive grants and selected to participate in critical FDA clinical trials.